Bangalore, India

ChanRe Rheumatology and Immunology Center and Research

Systemic Lupus Erythematosus

Rheumatoid Arthritis

Arthritis

Microscopic Polyangiitis

Granulomatosis with Polyangiitis

Baricitinib

Methylprednisolone

Prednisone

CP-690,550

Afimetoran

Lilly

Bristol-Myers Squibb (BMS)

Pfizer

Roche

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran.

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

ChanRe Rheumatology and Immunology Center and Research | Bangalore, India

Site insights

Work at this site?

Active trials

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Trial sponsors